New & Notable
How PBM reforms could push drugmakers into the pricing spotlight
The Consolidated Appropriations Act’s landmark PBM overhaul removes financial incentives tied to pharma list prices, potentially leaving drugmakers to defend their own practices.
— PharmaVoice
Lilly's GLP-1 diabetes pill beats Novo's Rybelsus in a head-to-head trial
Eli Lilly's GLP-1 pill, orforglipron, bested rival Novo Nordisk's Rybelsus in the first head-to-head late-phase diabetes trial but led to higher side effect rates.
Novo teams up with Vivtex to develop oral metabolic biologics
Novo Nordisk doubles down on oral drug delivery for the development of next-generation obesity and diabetes biologics, striking a licensing deal with Vivtex valued at up to $2.1 billion.
Novo, searching for a spark, spotlights new data for three-pronged obesity drug
Novo’s answer to a closely watched Lilly drug spurred roughly 20% weight loss after 24 weeks in a Phase 2 trial, results one of its executives claimed to be “differentiating.”
— BioPharma DiveHealthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
Viking Therapeutics pushes GLP-1/GIP obesity pill to phase 3
Viking Therapeutics is progressing the oral version of its leading drug candidate, VK2736, into phase 3 testing this year, following a mid-stage win.
-
AstraZeneca's GLP-1 pill succeeds in two mid-stage trials
AstraZeneca is moving its GLP-1 pill, elecoglipron, into phase 3 development after revealing positive results from two mid-stage studies, with final readouts slated for June.
-
Nearly half of TrumpRx drugs have generic options available
Of the 43 drugs listed on TrumpRx, 20 have generic versions available in the United States. And most others can be purchased through previously existing discount programs.
-
GLP-1 therapies set to top global drug sales in 2026
GLP-1 drugs are on track to dominate this year's global biopharmaceutical sales rankings, a recent report says, marking a shift in where the industry's biggest money-makers now sit.
-
ConcertAI unveils agentic AI tool to cut trial timelines, costs
ConcertAI has rolled out Accelerated Clinical Trials, an agentic AI platform that can cut trial timelines by 10–20 months and study design time by up to 50%, the company says.
-
Oracle launches AI data tool to expedite life sciences research
Oracle's new GenAI data platform was built to help pharmaceutical and life sciences companies speed up drug research and development using real-world health datasets.
Features
-
5 emerging AI/ML trends in clinical research
Emerging AI and machine learning tools are reshaping clinical research as trial sponsors continue to grapple with rising costs, lengthy timelines and low success rates.
-
5 trends defining the next wave of life sciences M&A
As the market rebounds, five key trends are shaping the next wave of mergers and acquisitions in the life sciences industry.
-
GLP-1 drugs primed for FDA approval in 2026
With Pharma titans Eli Lilly and Novo Nordisk continuing to duke it out for control of the GLP-1 market, both are seeking FDA approval for new drugs this year.
-
Blurring the line between GLP-1 compounders, counterfeiters
Weak regulatory oversight has allowed 503A compounding facilities to abuse customization rules, blurring the line between GLP-1 compounders and unregulated drug manufacturers.